[Renal cysts - A novel complication of crizotinib treatment for lung cancer]. / Kyste rénal sous crizotinib. Une nouvelle complication pour le pneumo-oncologue.

We report the case of a woman with an ALK positive lung adenocarcinoma, who developed bilateral complex renal cysts 17 months after the introduction of treatment with crizotinib. Clinical investigation led to the conclusion that the cysts were due to anticancer drug. Regression of the renal cysts was observed one month after cessation of the crizotinib. This case illustrates that specific and little known toxicities can occur with these novel molecules which have entered use for the management of lung cancer.

[Identification of occupational exposure in thoracic oncology: a Belgian experience]. / Apport du repérage des expositions professionnelles en oncologie thoracique: une expérience belge.

INTRODUCTION: In Belgium in 2008, the body responsible for compensating and indemnifying victims of occupational diseases recognized 62 cases of lung cancer, although 702 cases were expected. There is an "underreporting" of occupational lung cancer. This study aimed to assess the number of cases of occupational lung cancer in a Belgian hospital specialized in oncology. PATIENT AND METHOD: From September 1st, 2009 to January 31st, 2011, each new patient with lung cancer has been directed to a consultation identifying occupational exposure to lung carcinogens. RESULTS: Among 81 occupational histories, 28 patients (35%) were found to have been definitely or probably exposed to one or more lung carcinogens (known or suspected). These patients were all male, mostly blue collar workers. Thirteen compensation claims for occupational disease have been introduced: nine recognized, one rejected and three pending. CONCLUSION: This study demonstrates the importance of a physician trained in occupational diseases within a thoracic oncology unit in reducing the "underreporting" of occupational lung cancer and thus providing the victims with the compensation to which they are legitimately due.

Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.

UNLABELLED: Clinical variables, like stage and performance status (PS), have predictive and prognostic values in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy, not allowing adequate individual prediction. MicroRNA (miRNA) are non-coding RNAs regulating gene expression. In a prospective study, we assessed the predictive value for response and survival of tumour miRNA in NSCLC patients treated by 1st line cisplatin and vinorelbine. miRNA expression was analysed on a biopsy obtained during the diagnostic bronchoscopy, using TaqMan Low Density Arrays. The signature for response was derived using logistic regression with stepwise variable selection. The associations between overall survival and miRNA expression levels were estimated by using the Kaplan-Meier method, log-rank test, and Cox proportional hazard regression models to estimate the hazard ratios. In total, 38 patients with adequate tumour biopsies, treated with cisplatin-vinorelbine were included: male (n = 27), 80-100 Karnofsky PS (n = 27), adenocarcinoma (n = 20), stage IV (n = 30). One patient was considered not assessable for response but remained included in the survival analyses. Out of the 37 patients assessable for response, 16 partial responses (43%) were observed. A two miRNA signature (miR-149 and miR-375) was found predictive for response and was also associated to progression-free survival (p = 0.05). Using a linear combination of the miR CT values with Cox's regression coefficients as weights, we constructed a prognostic score for overall survival including four miRNA (miR-200c, miR-424, miR-29c and miR-124). The signature distinguished patients with good (n = 18) and poor (n = 20) prognosis with respective median survival times of 47.3 months (95% CI 29.8-52.4) and 15.5 months (95% CI 9.1-22.8) (p < 0.001; hazard ratio 21.1, 95% CI 4.7-94.9). CONCLUSIONS: miRNA signature allows predicting response and is of prognostic value for survival in patients with NSCLC treated with first line cisplatin and vinorelbine.

[An atypical presentation of bronchial adenocarcinoma]. / Une présentation atypique d'un adénocarcinome bronchique.

Currently, adenocarcinoma represents 41 % of primary lung cancers in women and 34 % in men. Thyroid metastases of lung cancer are rare and usually asymptomatic. We report the case of a patient presenting with stridor secondary to an enlarged multiple nodular thyroid accompanied by cervical lymphadenopathies accompanied by an enlarged and multiple nodular thyroid and by stridor. The final diagnosis was thyroid metastases of primary lung adenocarcinoma.